ArticleBiomolecules2019
Noninvasive Imaging of the Immune Checkpoint LAG-3 Using Nanobodies, from Development to Pre-Clinical Use.
Article in Biomolecules, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 54 citations in OpenAlex.
- Article
- Emerging ImmunoPET probes for precision cancer immunotherapy: molecular targets and translational applications.Frontiers in oncology · 2026Review
- Nanobodies as innovative immune checkpoint modulators: advancing cancer immunotherapy.Medical oncology (Northwood, London, England) · 2024Review
- ImmunoPET imaging of LAG-3 expression in tumor microenvironment withJournal for immunotherapy of cancer · 2024Article
- Anti-Idiotypic VHHs and VHH-CAR-T Cells to Tackle Multiple Myeloma: Different Applications Call for Different Antigen-Binding Moieties.International journal of molecular sciences · 2024Article
- Review
- Scrutiny of chimeric antigen receptor activation by the extracellular domain: experience with single domain antibodies targeting multiple myeloma cells highlights the need for case-by-case optimization.Frontiers in immunology · 2024Article
- Advancements in nuclear imaging using radiolabeled nanobody tracers to support cancer immunotherapy.Immunotherapy advances · 2024Review
- NANOBODYInternational journal of molecular sciences · 2023Review
- Article
- Peptide-based PET imaging agent of tumor TIGIT expression.EJNMMI research · 2023Article
- Nontoxic Fluorescent Nanoprobes for Multiplexed Detection and 3D Imaging of Tumor Markers in Breast Cancer.Pharmaceutics · 2023Review
- Development and evaluation of nanobody tracers for noninvasive nuclear imaging of the immune-checkpoint TIGIT.Frontiers in immunology · 2023Article
- Imaging cellular immunotherapies and immune cell biomarkers: from preclinical studies to patients.Journal for immunotherapy of cancer · 2022Review
- Imaging immunity in patients with cancer using positron emission tomography.NPJ precision oncology · 2022Review
- Application of Noninvasive Imaging to Combined Immune Checkpoint Inhibitors for Breast Cancer: Facts and Future.Molecular imaging and biology · 2022Review
- ImmunoPET: harnessing antibodies for imaging immune cells.Molecular imaging and biology · 2022Review
- Promise and challenges of clinical non-invasive T-cell tracking in the era of cancer immunotherapy.EJNMMI research · 2022Review
- Evaluation of single domain antibodies as nuclear tracers for imaging of the immune checkpoint receptor human lymphocyte activation gene-3 in cancer.EJNMMI research · 2021Article
- Single-Domain Antibody Nuclear Imaging Allows Noninvasive Quantification of LAG-3 Expression by Tumor-Infiltrating Leukocytes and Predicts Response of Immune Checkpoint Blockade.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibition (ICI) is a promising cancer therapy, which has progressed rapidly from a preclinical concept to clinical implementation. Commonly considered targets in ICI are CTLA-4, PD-1/PD-L1, and LAG-3, and the list grows. As ICI is generally only beneficial for a subset of patients, there is a need to select patients that are eligible for therapy as well as to monitor therapy response. There is growing interest to do this noninvasively, by molecular imaging with target-specific tracers. To this day, noninvasive imaging has focused on CTLA-4 and PD-1/PD-L1, while there is no noninvasive tool available to accurately assess LAG-3 expression in vivo. In this proof-of-concept study, we developed nanobodies, the smallest functional fragments from camelid heavy chain-only antibodies, to noninvasively evaluate mouse LAG-3 expression using single photon emission computed tomography (SPECT)/CT imaging. The in vitro characterization of 114 nanobodies led to the selection of nine nanobodies binding to mouse LAG-3. The injection of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.